* A study of 90 AYAs in Peru showed a 91% overall response rate to R-CHOP, with 5-year overall survival (OS) and progression-free survival (PFS) rates of 79% and 67%, respectively.
* Despite comparable outcomes to adults, those with relapsed/refractory disease had poor prognosis, highlighting the need for better and more accessible treatment options for AYAs with DLBCL.
* Among 118 patients treated between 2010 and 2019, those with RDW-CV values over 14% showed significantly lower overall survival rates (34% vs. 45%) and higher lymphoma-specific mortality (54% vs. 34%) over 4 years.
* The study suggests that high RDW-CV is a potential and easy-to-use prognostic marker for evaluating risk in PTCL patients, indicating a need for further validation in future research. *